Smruthi Organics Ltd (BSE: 540686) is a Solapur, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹199 Cr, it ranks #2,652 by market cap among the 6,197 Indian listed companies on FinBizNet, and #56 of 86 in Medicinal Chemicals and Botanical Products. At ₹170.00 (as of 16 Nov 2026), the share price is 7.1% below its 52-week high of ₹183.00 and 78.9% above its 52-week low of ₹95.00. The share price is up 30.6% over one year and up 33.0% over three months.
| Current Price | ₹170.00 |
|---|---|
| Market Cap | ₹199 Cr |
| BSE Code | 540686 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 57.7 |
| Return on Equity | 4.72% |
| Return on Assets | 4.08% |
| 52-Week Range | ₹95.00 – ₹183.00 |
| 1-Year Price Change | +30.6% |
| 3-Month Price Change | +33.0% |
| Beta (1Y) | 0.39 |
| Dividend Yield | 0.87% |
| Headquarters | Solapur, Maharashtra |
| Website | smruthiorganics.com |
| Revenue | ₹29 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 10.0% |
| EPS (Basic) | ₹2.57 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Smruthi Organics Ltd reported revenue of ₹29 Cr in Q1 FY27, up 54.3% from ₹19 Cr in Q1 FY26 and up 0.7% from ₹29 Cr in Q4 FY26. It posted a net profit of ₹3 Cr for the quarter, against a net loss of ₹1 Cr in Q1 FY26. Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹19 Cr (Q1 FY26) to ₹38 Cr (Q4 FY25). The company reported a net loss in 1 of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹29 Cr | ₹3 Cr | 10.0% |
| Q4 FY26 | ₹29 Cr | ₹1 Cr | 3.7% |
| Q3 FY26 | ₹22 Cr | ₹1 Cr | 6.3% |
| Q2 FY26 | ₹32 Cr | ₹2 Cr | 6.5% |
| Q1 FY26 | ₹19 Cr | −₹1 Cr | −5.8% |
| Q4 FY25 | ₹38 Cr | ₹2 Cr | 5.9% |
Standalone figures (₹ crore, XBRL filings).
Delivery averaged 76.2% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Smruthi Organics Limited manufactures and markets active pharmaceutical ingredient (API) products to India. The company provides API for cardiovascular that includes amlodipine besilate, losartan potassium, telmisartan, s - amlodipine besilate, s - amlodipine malelate, and valsartan; for anti diabetic, which comprises metformin HCL, vildagliptin, teneligliptin, and dapagliflozin; and for anti infectives that consists of ciprofloxacin HCL, diloxanide furoate, norfloxacin, and pefloxacin mesylate, as well as ticagrelor for anti platelets. It also offers drug intermediates, such as amlodipine base, s-amlodipine base, and phthaloyl amlodipine. In addition, the company is developing empagliflozin for anti-diabetics; and apixaban and rivaroxaban for anti-platelets. It also exports its products. The company was incorporated in 1989 and is headquartered in Solapur, India.
1. Bulk Drugs and Drug Intermediates-This segment manufactures active pharmaceutical ingredients, such as bulk drugs and drug intermediates. 2. Formulation Division-This segment offers finished dosage formulations.
1. API-99.8% 3. Formulation-0.2%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Smruthi Organics Ltd | ₹199 Cr | 57.7 | 4.72% | ₹29 Cr | +30.6% |
Listed by market capitalisation. Ratios are shown for context only.
Smruthi Organics Ltd is trading at ₹170.00, with a market capitalisation of ₹199 Cr.
Smruthi Organics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Smruthi Organics Ltd has a P/E of 57.7 and a return on equity of 4.72%.
Smruthi Organics Ltd is listed on the BSE under the scrip code 540686.
Smruthi Organics Ltd's share price is up 30.6% over one year and up 33.0% over three months. Its 52-week range is ₹95.00 to ₹183.00.
In Q1 FY27, Smruthi Organics Ltd reported revenue of ₹29 Cr and net profit of ₹3 Cr, with basic EPS of ₹2.57 (standalone, parsed from the company's exchange filing).
Smruthi Organics Ltd reported revenue of ₹29 Cr in Q1 FY27, up 54.3% from ₹19 Cr in Q1 FY26 and up 0.7% from ₹29 Cr in Q4 FY26.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.